Director, Financial Planning & Analysis

The Mission

Clarify is an outcomes company. We partner with 60+ health systems to do the work that most analytics vendors walk away from. Across 900 million annual referrals and $1 trillion in downstream spending, we identify where mission and margin are falling out of alignment, and then we embed with the people who can change it: the liaison in the field, the contract negotiator at the table, the service line leader running the plan.

We bring the most complete picture of care economics in healthcare. 300 million patient journeys. 5.6 trillion price transparency rates. Episode-level quality across every major payer contract. Clarify Meridian puts that picture to work at the point of every decision. But the picture is not what we deliver. The outcomes are.

The Opportunity

Clarify is looking for a Director, Financial Planning & Analysis to build and own the financial models and analyses that power decision-making at a fast-scaling, AI-first healthcare technology company. This role sits within Finance and reports to the CFO. You'll build the financial models and analyses that inform the CFO's decisions, help shape how Clarify's financial story is told to the company, the Board, and outside stakeholders, and support the CFO on fundraising, M&A, and other high-stakes work. This is a hands-on, individual-contributor role for someone trained in a demanding, high-accountability environment - investment banking, private equity, hedge funds, or specialty/credit lending - who is ready to move from advising or evaluating businesses to owning the financial engine of one.

We recently acquired Loyal Health to build the industry's first closed-loop network intelligence and patient activation platform, and we are actively transitioning our commercial model from traditional SaaS subscriptions to Meridian, a tech-enabled outcomes partnership where our economics are tied to the results we deliver for health systems. That shift - modeling success-fee revenue, at-risk contracts, and multi-year outcomes-based partnerships alongside our existing SaaS book - is exactly the kind of complex, non-linear financial modeling problem that will keep this role interesting for years, not months.

You'll work directly on fundraising, M&A evaluation and integration, and long-range forecasting for a business model most finance professionals have never had to model before - the kind of access and trust that comes from being the person whose numbers the CFO relies on. You'll also partner closely with Operations and Sales on revenue recognition, ARR tracking, and the sales-ops-adjacent mechanics that keep our commercial engine honest. Healthcare experience is not required but the analytical rigor and self-taught intensity to get there fast absolutely is.

Does this sound like you?

You were trained in a demanding, detail-intensive finance environment - investment banking, private equity, hedge funds, or specialty/credit lending

You're a self-directed learner who has successfully made a hard pivot before - from banking or investing into an operating company, a new industry, or a new function - and you figured it out fast without a playbook

You're quantitatively fearless - three-statement models, scenario analysis, and complex revenue mechanics don't intimidate you, and you'd rather build the model yourself than wait for someone else to hand you one

You're AI-native in your workflow - you use Claude, ChatGPT, or similar tools daily to accelerate modeling, diligence, and reporting, and you're always looking for the faster way to get to a defensible answer

You bring rigor and ownership to the numbers, not just back-office analysis - the CFO relies on you because your models hold up under scrutiny and your work is airtight

You're comfortable being the most rigorous person in the room on structure and diligence, while still moving at startup speed - you default to shipping a solid answer today over a perfect one next week

You want ownership, not oversight - you'd rather build the financial infrastructure for a company you can point to than be one more analyst on someone else's deal